Category: Regions

AstraZeneca’s cancer drug shows positive result in NSCLC treatment
May 12, 2017 Off

AstraZeneca’s cancer drug shows positive result in NSCLC treatment

By Dino Mustafić

AstraZeneca and its subsidiary MedImmune, have reported positive results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-controlled multi-centre trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy.

Lilly welcomes new member of executive committee
May 10, 2017 Off

Lilly welcomes new member of executive committee

By Dino Mustafić

Leigh Ann Pusey will join Eli Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017. She will be a member of Lilly’s executive committee reporting directly to president and chief executive officer, David A. Ricks.

Anavex Life Sciences reports $1.5M net loss for Q1 2017
May 10, 2017 Off

Anavex Life Sciences reports $1.5M net loss for Q1 2017

By Dino Mustafić

Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, todayhas reported financial results for the fiscal quarter ended March 31, 2017.​

AstraZeneca’s asthma drug study fails expectations
May 10, 2017 Off

AstraZeneca’s asthma drug study fails expectations

By Dino Mustafić

AstraZeneca and its subsidiary MedImmune have reported that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate (AAER) in the overall population of severe, uncontrolled asthma patients, compared with placebo in STRATOS 1, the first of two pivotal Phase III trials.